Equities

Guided Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GTHP:QBB

Guided Therapeutics Inc

Actions
  • Price (USD)0.39
  • Today's Change0.04 / 11.43%
  • Shares traded3.40k
  • 1 Year change+307.65%
  • Beta0.5498
Data delayed at least 15 minutes, as of Mar 04 2026 20:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.

  • Revenue in USD (TTM)178.00k
  • Net income in USD-2.80m
  • Incorporated1992
  • Employees4.00
  • Location
    Guided Therapeutics IncSuite 300, 4955 Avalon Ridge PkwyNORCROSS 30071United StatesUSA
  • Phone+1 (770) 242-8723
  • Fax+1 (770) 242-8639
  • Websitehttps://www.guidedinc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Global Innovative Platforms Inc30.00k-647.22k24.24m52.00--147.33--808.04-0.0156-0.01560.00070.00350.1607-------346.65---441.46-------2,157.40------0.0185-------427.35------
Harvard Bioscience Inc87.37m-53.84m25.65m330.00--1.82--0.2936-1.22-1.221.980.31560.83521.587.01264,760.60-51.46-4.48-81.52-5.4756.9457.18-61.62-6.180.4081-0.56860.7071---16.14-4.12-263.25--21.83--
Inspira Technologies Oxy BHN Ltd289.00k-11.21m26.57m38.00--13.77--91.93-0.4606-0.46060.01280.04460.04170.52810.66597,605.26-161.61-109.16-302.02-145.380.692---3,879.24--0.9002--0.00------2.06--39.54--
PetVivo Holdings Inc1.11m-10.21m27.31m24.00--7.96--24.57-0.3857-0.38570.04110.09810.29690.78744.2546,318.33-265.20-195.28-557.27-346.3366.0574.58-893.26-1,163.490.787-4.520.00--16.91216.0823.33--49.21--
Phaos Technlgy Hldngs (Cayman) Limited131.54k-100.00bn29.20m--------221.96-------0.0598------------------------0.3176------------------
Vaso Corp89.11m2.59m29.91m298.0011.581.069.030.33570.01470.01470.50650.16051.1334.0210.28299,030.203.277.375.3614.5660.9159.172.915.991.61--0.01--7.092.82-80.21--3.81--
Myomo Inc41.64m-12.02m30.93m184.00--2.11--0.7427-0.2885-0.28851.010.38051.653.969.23226,321.70-47.71-55.96-70.30-77.4066.5669.74-28.86-52.922.10--0.2148--69.1753.3624.10--92.10--
RenovoRx Inc928.00k-11.11m31.19m10.00--3.86--33.61-0.4375-0.43750.03120.22040.0874----92,800.00-104.58-121.57-126.33-166.5067.78---1,196.66-90,830.235.68--0.00------13.86------
Femasys Inc2.06m-19.80m31.90m69.00--5.66--15.47-0.7198-0.71980.070.09630.12940.19734.3429,876.81-124.24-63.09-214.46-74.3063.0566.63-960.53-961.820.6131-9.720.5982--51.9711.89-32.07--4.01--
Guided Therapeutics Inc178.00k-2.80m32.60m4.00------183.17-0.0386-0.03860.0025-0.06750.16540.108344.5044,500.00-244.61-129.80----62.9244.19-1,478.65-4,184.720.0334-4.13-----92.86-27.9331.07------
Precision Optics Corporation Inc24.42m-6.92m33.27m90.00--3.57--1.36-0.9286-0.92863.251.211.215.445.83271,288.60-34.24-13.63-57.54-19.519.7029.56-28.33-11.580.6188-36.730.1454---0.068513.98-95.85--7.81--
Vivos Inc48.63k-3.01m36.15m10.00--16.58--743.28-0.0068-0.00680.00010.00480.0275--10.03---170.12-166.49-178.25-242.01-127.332.81-6,191.01-11,105.9819.81--0.00--43.5924.13-0.5424------
TELA Bio Inc77.06m-39.00m36.74m209.00--21.75--0.4768-0.8863-0.88631.750.03861.342.016.85368,684.20-68.06-51.29-96.57-60.7067.2366.26-50.61-88.022.62-7.250.9638--18.5635.0218.91---18.18--
Ekso Bionics Holdings Inc12.80m-11.92m37.99m50.00--4.20--2.97-5.09-5.095.282.540.54741.271.76255,980.00-50.02-37.99-76.46-49.4753.4852.48-91.37-86.201.07--0.31---28.607.58-5.22------
EUDA Health Holdings Ltd5.16m-2.06m39.61m117.0050.96----7.680.01550.08760.1483-0.09982.49--17.1044,104.96-100.77------22.39---40.53--0.2084-46.54----8.22---108.62------
Neuroone Medical Technologies Corp8.72m-6.83m39.92m18.00--6.22--4.58-0.1648-0.16480.19360.12701.162.193.47484,231.70-90.61-113.64-111.55-152.0854.8760.94-78.34-223.445.09--0.1119--250.3544.4170.73---7.76--
Data as of Mar 04 2026. Currency figures normalised to Guided Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

5.08%Per cent of shares held by top holders
HolderShares% Held
Auctus Fund Management LLCas of 18 Mar 20254.25m5.08%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.